TXA9, a cardiac glycoside from Streptocaulon juventas, exerts a potent anti-tumor activity against human non-small cell lung cancer cells in vitro and in vivo
Authors:
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science and Technology (2010ZX09401-304)
- Natural Science Foundation of China (30973958)
This publication has 22 references indexed in Scilit:
- Preclinical strategies targeted at non-small-cell lung cancer signalling pathways with striking translational falloutDrug Discovery Today, 2013
- Maintenance therapy for NSCLC: Consensus and controversyChinese Journal of Cancer Research, 2011
- Inhibitory Activity of a Phytochemically Characterized Fraction fromStreptocaulon juventason Lung Cancer in Nude MicePlanta Medica, 2009
- Novel therapeutic applications of cardiac glycosidesNature Reviews Drug Discovery, 2008
- The Sodium Pump α1 Subunit as a Potential Target to Combat Apoptosis-Resistant GlioblastomasNeoplasia, 2008
- Lessons from natural moleculesNature, 2004
- Mechanisms of sodium pump regulationAmerican Journal of Physiology-Cell Physiology, 2000
- Prolonged digitoxin half-life in very elderly patientsAge and Ageing, 1998
- Effects of arrhythmia-producing concentrations of digitoxin on mechanical performance of cat myocardiumAmerican Heart Journal, 1983
- Digitalis toxicity: Epidemiology and clinical use of serum concentration measurementsThe American Journal of Medicine, 1975